Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer

European Journal of Cancer

Volumn 36, Issue 10, 2000, Pages 1258-1268

  DeClerck, Y A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Extracellular matrix; Metalloproteinases; Tissue inhibitor of metalloproteinases; Tumour invasion

Indexed keywords

DISINTEGRIN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

CANCER; CANCER INVASION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; CONFERENCE PAPER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; STROMA CELL; TUMOR CELL;

EXTRACELLULAR MATRIX; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; NEOPLASMS; STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0034123653     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00094-0     Document Type: Conference Paper

References (92)

1. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986, 46, 1-7.
2. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284, 67-68.
3. Pozzatti R, Muschel RJ, Williams J, et al. Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials. Science 1986, 232, 223-227.
4. Garbisa S, Negro A, Kalebic T, et al. Type IV collagenolytic activity linkage with the metastatic phenotype induced by ras transfection. Adv Exp Med Biol 1988, 233, 179-186.
5. Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1990, 1, 137-152.
6. Nakajima M, Welch DR, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987, 47, 4869-4876.
7. Barrett AJ, Rawlings ND, Woessner JF, eds. Handbook of Proteolytic Enzymes. Academic Press, 1998.
8. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999, 274, 21491-21494.
9. Birkedal Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993, 4, 197-250.
10. Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999, 55, 639-652.
11. Millis AJ, Hoyle M, McCue HM, Martini H. Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts. Exp Cell Res 1992, 201, 373-379.
12. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem Hoppe Seyler 1997, 378, 151-160.
13. Dedhar S. Integrins and tumor invasion. Bioessays 1990, 12, 583-590.
14. Suzuki K, Lees M, Newlands GFJ, Nagase H, Woolley DE. Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Blochem J 1995, 305, 301-306.
15. Murphy G, Allan JA, Willenbrock F, Cockett MI, O'Connell JP, Docherty AJ. The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem 1992, 267, 9612-9618.
16. Allan JA, Hembry RM, Angal S, Reynolds JJ, Murphy G. Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. J Cell Sci 1991, 99, 789-795.
17. Gohlke U, Gomis Ruth FX, Crabbe T, Murphy G, Docherty AJ, Bode W. The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEES Lett 1996, 378, 126-130.
18. Murphy G, Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997, 15, 511-518.
19. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85, 683-693.
20. Salo T, Turpeenniemi Hujanen T, Tryggvason K. Tumorpromoting phorbol esters and cell proliferation stimulate secretion of basement membrane (type IV) collagen-degrading metalloproteinase by human fibroblasts. J Biol Chem 1985, 260, 8526-8531.
21. Collier IE, Wilhelm SM, Eisen AZ, et al. H-ras oncogenetransformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988, 263, 6579-6587.
22. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 1989, 86, 8207-8211.
23. Strongin AY, Collier IE, Krasnov PA, Genrich LT, Marmer BL, Goldberg GI. Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Int 1993, 43, 158-162.
24. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370, 61-65.
25. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995, 375, 244-247.
26. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270, 5331-5338.
27. Kinoshita T, Sato H, Okada A, et al. TIMP-2 promotes activation of progelatinase a by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998, 273, 16098-16103.
28. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999, 286, 113-117.
29. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998, 161, 6845-6852.
30. Docherty AJ, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identify to erythroidpotentiating activity. Nature 1985, 318, 66-69.
31. Boone TC, Johnson MJ, DeClerck YA, Langley KE. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. Proc Natl Acad Sci USA 1990, 87, 2800-2804.
32. Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 1994, 19, 86-90.
33. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996, 271, 30375-30380.
34. Williamson RA, Smith BJ, Angal S, Murphy G, Freedman RB. Structural analysis of tissue inhibitor of metalloproteinases-1 (TIMP-1) by tryptic peptide mapping. Biochim Biophys Acta 1993, 1164, 8-16.
35. Gomis-Rüth FX, Maskos K, Betz M, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997, 389, 77-81.
36. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991, 30, 8097-8102.
37. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995, 131, 275-278.
38. Wolfsberg TG, Straight PD, Gerena RL, et al. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev Biol 1995, 169, 378-383.
39. Stone AL, Kroeger M, Sang QXA. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase containing proteins (review). J Protein Chem 1999, 18, 447-465.
40. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol 1998, 10, 654-659.
41. Amour A, Slocombe PM, Webster A, et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEES Lett 1998, 435, 39-44.
42. Killar L, White J, Black R, Peschon J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann NY Acad Sci 1999, 878, 442-452.
43. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature 1997, 385, 729-733.
44. Rooke J, Pan D, Xu T, Rubin GM. KUZ, a conserved metalloprotease-disintegrin protein with two roles in Drosophila neurogenesis. Science 1996, 273, 1227-1231.
45. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 1999, 154, 1489-1501.
46. Yavari R, Adida C, Bray-Ward P, Brines M, Xu T. Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia. Hum Mol Genet 1998, 7, 1161-1167.
47. Wu E, Croucher PI, McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 1997, 235, 437-442.
48. Kuno K, Terashima Y, Matsushima K. ADAMTS-1 is an active metalloproteinase associated extracellular matrix. J Biol Chem 1999, 274, 18821-18826.
49. Abbaszade I, Liu RQ, Yang F, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999, 274, 23443-23450.
50. Tortorella MD, Burn TC, Pratta MA, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999, 284, 1664-1666.
51. Vazquez F, Hastings G, Ortega MA, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999, 274, 23349-23357.
52. Poulsom R, Pignatelli M, Stetler-Stevenson WG, et al. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992, 141, 389-396.
53. Basset P, Wolf C, Chambon P. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat 1993, 24, 185-193.
54. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997, 15, 535-541.
55. McDonnell S, Chaudhry V, Mansilla-Soto J, Zeng ZS, Shu WP, Guillem JG. Metastatic and non-metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo. Clin Exp Metastasis 1999, 17, 341-349.
56. Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T, Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer 1995, 75, 1516-1519.
57. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994, 10, 199-206.
58. Una JA, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997, 57, 4882-4888.
59. Hoyhtyea M, Fridman R, Komarek D, et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994, 56, 500-505.
60. Rao JS, Yamamoto M, Mohanam S, et al. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 1996, 14, 12-18.
61. Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998, 58, 2209-2216.
62. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996, 149, 273-282.
63. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999, 13, 1382-1397.
64. Nielsen BS, Timshel S, Kjeldsen L, et al. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996, 65, 57-62.
65. Himelstein BP, Canete Soler R, Bernhard EJ, Muschel RJ. Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci 1994, 107, 477-486.
66. Zucker S, Biswas C. Tumour collagenase-stimulating factor: a paracrine stimulator of fibroblast production of matrix metalloproteinases in cancer. Bull Inst Pasteur 1994, 92, 284-290.
67. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cellderived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995, 55, 434-439.
68. Guo H, Majmudar G, Jensen TC, Biswas C, Toole BP, Gordon MK. Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene 1998, 220, 99-108.
69. Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998, 139, 1338-1345.
70. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells -Role of flt-1. Circ Res 1998, 83, 832-840.
71. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase a and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998, 55, 29-42.
72. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993, 73, 161-195.
73. Fernandez HA, Kallenbach K, Seghezzi G, et al. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res 1999, 82, 156-162.
74. Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 1998, 8, 437-441.
75. Roskelley CD, Srebrow A, Bissell MJ. A hierarchy of ECMmediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol 1995, 7, 736-747.
76. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91, 439-442.
77. Sassone Corsi P. Goals for signal transduction pathways: linking up with transcriptional regulation. EMBO J 1994, 13, 4717-4728.
78. Roskelley CD, Desprez PY, Bissell MJ. Extracellular matrixdependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Natl Acad Sci USA 1994, 91, 12378-12382.
79. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995, 267, 891-893.
80. Sympson CJ, Bissell MJ, Werb Z. Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 1995, 6, 159-163.
81. Alexander CM, Howard EW, Bissell MJ, Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J Cell Biology 1996, 135, 1669-1677.
82. Boudreau N, Werb Z, Bissell MJ. Suppression of apoptosis by basement membrane requires three-dimensional tissue organiza-tion and withdrawal from the cell cycle. Proc Natl Acad Sci USA 1996, 93, 3509-3513.
83. Boudreau N, Bissell MJ. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 1998, 10, 640-646.
84. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279, 509-514.
85. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Ann Rev Cell Dev Biol 1995, 11, 549-599.
86. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994, 91, 8856-8860.
87. Petitclerc E, Stromblad S, von Schalscha TL, et al. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999, 59, 2724-2730.
88. Zutter MM, Santoro SA, Staatz WD, Tsung YL. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci USA 1995, 92, 7411-7415.
89. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994, 54, 5467-5473.
90. Henriet P, Blavier L, DeClerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999, 107, 111-119.
91. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Natl Med 1999, 5, 662-668.
92. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100, 57-70.